Irodalom
1. Kenneth R.. De Vault, Donald O: Castell, Updated
Guidelines for the Diagnosis and Treatment of
Gastroesophageal Reflux Disease The American
Journal of Gastroenterology Vol.94,No.6 1434-1442
,1999.
2. J C Fang,I Sarosiek, Cholinergic blockade inhibits
gastro-oesophageal reflux and transient lower oesophageal
sphincter relaxation through a central mechanism GUT
Volume 44(5) May 1999 603-607
3. Daniel Sifrim , Richard Holloway, Effect of
Sumatriptan, a 5HT1 Agonist, on the Frequency of
Transient Lower Oesophageal Sphincter Relaxations and
Gastroesophageal Reflux in Healthy Subjects The
American Journal of Gastroenterology Vol.94.No.11.1999
3158-3164
4. M.A. van Herwaarden, M.Samson, The Motilin Agonist
ABT-229, A Potential Drug For The Treatment of GERD?
GUT 1999;45 (Suppl V)A40
5. M.Katschinski, J.Schirra, The Efficacy of Novel 40 mg
Extended Release Formulation of Cisapride To Improve
Gastrooesophageal Reflux GUT 1999; 45 (Suppl V) A40
6. T.Havelund, T.Lind, Quality of Life in- Patients With
Heartburn But Without Esophagitis Effects of Treatment
With Omeprazole. American Journal of Gastroenterology
Vol.94,No.7. 1782-17891999
7. L.Lundell, P.Miettinen, H.Myrvold A Randomised
Comparison Between Omeprazole and Anti-Reflux
Surgery in Management of Chronic Gaastroeosophageal
Reflux Disease.Report On Five Year Follow-up GUT
1999; 45 (Suppl V), A40
8. S.Sacher-Huvelin. J.Gurnay ASR And Quality of Life
GUT 1999 ;45(Supple V),A40.
9. McNamara ,D;O’Morian,C Gastro-Oesopphageal
Reflux Disease and Hp.:an Intricate Relation GUT
Volume 45 Supplement No 1 July 113-117
10. El-Serag, H B;Sonnernberg Corpus Gastritis is
protective against reflux oesophagitis GUT, Volume
45(2).August 1999.181-185
11.Justin C.Y. Wu, Joseph J.Y.Sung Prevalence and
Distribution of Helicobacter Pylori Gastroesophageal
Reflux Disease: A Study from The East.The American
Journal of Gastroenterology Vol.94,No.7 1999 1791-1794
12. Peters FT. Kuipers EJ. The Influence of Helicobacter
Pylori on Oesophageal Acid Exposure in GERD
Alimentary Pharmacology & Therapeutics
13(7):921-6,1999 Jul.
13. F.Baldí, R.Cappiello H.Pylori Status And Outcome Of
Long-Term PPI Treatment After healing Of Erosiv
Oesophagitis GUT 1999; (Suppl V) A41
14. Khek Yu Ho, Jin Yong Kang Reflux Oesophagitis
Patients in Singapore Have Motor and Acid Exposure
Abnormalities Similar to Patients in the Western
Hemisphere The American Journal of Gasroentrology
Vol.94,No.5.1999 1186-1191
15. Prof. Dr. Tulassay Zsolt A Helicobacter pylori és a
gastrooesophagealis reflux betegség European Journal of
Gastroenterology & Hepatology Magyar Kiadás
III.évf.3.szám 1999 május 81-84
16. Irene Lluch, Juan F.Ascaso Gastrooesophageal Reflux
in Diabetes Mellitus The American Journal of
Gastroenterology Vol.94,No,4, 1999, 919-924
17. R.H.Holloway, M.Horowitz Relationship Between
Esophageal Motility and Transit in Patients with Type I
Diabetes Mellitus The American Journal of
Gastroenterology Vol.94,No.11,1999 3151-3157
18. Angel Aalvarez-Sanchez, Enrique Rey Does
Progesterone Fluctuation Across the Menstrual Cycle
Predispose to Gastroesophageal Reflux? The American
Journal of Gastroenterology Vol.94,No.6 1999 1469-1471
19. Prof. Dr. Papp János A Barrett-Oesophagus
Gasztroenterológia 1. évfolyam 2. szám 1999. augusztus
33-47
20. Asadi M, et al. Prospective Multivariate Analysis of
Cardia Intestinal Metaplasia (CIM) in Consecutive
Patients for Upper Gastroscopy. Gastroenterology 1999;
116(4):A115
21. Sharma P, et al. Cardia Intestinal Metaplasia(CÍM)
Relationship to H.Pylori, Barrett’s Esophagus and Erosive
Eesophagitis. Gastroenterology 1999;116(4);A308
22. Wolf C, et al Cardiac Mucosa-prevalence and
Associatios with Intestinal Metaplasia, Age and
Helicobacter pylori. Gastroenterology 1999; 116(4):A 356
23. Sharma,et al. Relativ Risk of Dysplasia for Patients
with Intestinal Metaplasia in the Distal Esophagus Versus
in Gastric cardia. Gastroenterology 1999 116(4),A:308
24. Wolf c, et al. Epidemiology and Clinical
Characteristics of Intestinal Metaplasia at the
Esophagogastric Junction. Gastroenterology
1999;116(4):A356
25. Vaezi Mf, et al. Cytokeratin Stains to Distinguish
Short-Segment Barrett Esophagus from Intestinal
Metaplasia of the Esophagogastric Junction.
Gastroenterology 1999,116(4)A:340
26. Ormsby AH, et al. Cytokeratin Subsets Distinguish
Barrett’s Esophagus from Gastric Intestinal Metaplasia in
Endoscopic Biopsy Specimens. Gastroenterology
1999;116(4):A273
27. El-Zymaty HMT et al. Cytokeratin Expression in
Barrett and Intestinal Metaplasia in the Stomach.
Gastroenterology 1999;116(4):A155
28. Griffel LH,et al. Cellular Phenotype of „cardia type”
Barrett’s Epithelium Gastroenterology 1999;116(4):A177
29. Quinonez N, et al. Prevalence of Barrett’s Esophagus
in Guatemalan Hispanics with Reflux Esophagitis.
Gastroenterology 1999;116(4):A288
30.Amarapurkar AD. et al. Barrett’s Esophagus Indian
Journal of Pathology and Microbiology. 41 (4):431-5,1998
Oct.
31. Conio M, et al. Barret’s Esophagus and
Adenocarcinoma. Prevalence and Incidence in Olmsted
County, Minnesota. Gastroenterology 1999; 116 : A 384
32. Watson A, et al. Changing Incidence of
Columnar-lined (Barrett’s) Oesophagus in the UK.
Gastroenterology 1999; 116: A 351
33. Alan J. Cameron,M.D. Barrett’s Oesophagus :
Prevalence and Size of Hiatal Hernia The American
Journal of Gastroenterology Vol.94,No.8.1999 2054-2059
34. C.Pehl, A. Waizenhoefer Effect of Low and High Fat
Meals on Lower Esophageal Sphincter Motility and
Gastroesophageal Reflux in Healthy Subjects The
American Journal of Gastroenterology Vol.94,No5. 1999
1193-1198
35. Nehra, D;Howell Toxic Bile Acid in
Gastro-Oesophageal Reflux Disease: Influence of Gastric
Acidity GUT, Volume 44(5).May 1999.598-602
36. Oberg S. DeMeester The Extent of Barrett’s
Esophagus Depends on the Status of the lower Esophageal
Sphincter and Degree of Esophageal Acid Exposre
Journal of Thoracic& Caediovascular
Surgery.117(3):572-80,1999 Mar.
37. Gostout C J, et al. Long-Segment Barrett’s Esophagus:
Is it Associated with Lower Esophageal Sphincter Pressure
and Increased Gastroesophageal Reflux Compared to
Short Segment Barret’s Esophagus? Gastrointestinal
Endoscopy 1999;49(4) :AB 51
38. Dixon J, et al. Mucus Gel Barrier Absent in Normal
Esophagus but Present in Barrett’s Esophagus.
Gastroenterology 1999; 116(4) : A 149
39. Kandil H M, et al. Cyclooxygenase-2(COX-2)
Expression in Barrett’s Esophagus. Gastroenterology
1999; 116(49 : A 431
40. Shirvani V, et al. Cyclooxygenase-2 Expression in
Barrett’s Esophagus and Esophageal Adenocarcinoma: Ex
Vivo Induction by Bile Salts and Acid Exposure.
Gastroenterology 1999; 116(4) A: 337
41. Poplawsky C, et al. Could Treatment with Low Dose
Nonsteroidal Anti-Inflammaory Drugs Help to Accelarate
Regression of Barrett’s Esophagus Potential Future
Therapeutic Challanges. Gastroenterology 1999;
116(4):A301
42. Hackelsberger A, et al. Mucosal Proliferation in
Specialized Columnar Metaplasia and Intestinal
Metaplasia of the Cardia Gastroenterology
C1999,116(4):A180
43. Lord RV, et al. Telomerase Reverse Transcriptase
Activation in Barrett’s Esophagus and Barrett’s
Adenocarcinomas. Gastroenterology 1999;116(4):A133
44. Gopal DV, Et al. Risk Factors for Dysplasia in Patients
with Barrett’s Esophagus: Results from Multicenter
Consortium Gastroenterology 1999; 116(4): A175
45. Rodica Ouatu-Lascar, Rebecca C. Fitzgerald
Differentation and Proliferation in Barrett’s Oesophagus
and the Effects of Acid suppression Gastroenterology
1999;Vol. 117; No. 2 .327-335
46. Yassin R, et al. A Novel, Highly Effective Low Cost
Method for Identifying p53 Mutations in Barrett’s
Metaplasia. Gastroenterology 1999; 116(4):A363
47. Casem H, et al. Microsatellite Analises Indentifies an
Extended Haplotype at the TNF Locus Associated with
Barrett’s Esophagus. Gastroenterology 1999; 116(4):
A433
48. LI AGK et al. The Transcriptional Activator SOX-4 is
Overexpressed in Displastic Barrett’s Epithelium and
Esophageal Adenocarcioma. Gasrtoenterology 1999;
116(4) : A 453
49. MacDonald CE, et al. Screening in Patiens with
Barrett’s Mucosa. Is There a Need for an Intensive Biopsy
Protocol? Gastroenterology 1999; 116(4) : A241
50. Sontag et al. Barrett’s High Grade Dysplasia:
Surviallance Endoscopy Once a Year is Sufficient in Most
Patients. Gastroenterology 1999; 116(4):A304
51. Sontag S J et al. Barrett’s Low Grade Dysplasia and
Fear; Yearly Endoscopy is Not Justified Surviellance
Every 2-3 Years Detects all Cancers Early.
Gastroenterology 1999; 116(4) : A316
52. Lipscomb S J et al. The Incidence of High Grade
Dysplasia and Adenocarcioma Among Patients with
Barrett’s Esophagus: a Cohort of 154 Patients Followed
for a Total of 471 Patients-Years. Gastroenterology 1999
116(4):A238
53. Provanzale D. Schmitt C . Barrett’s Esophagus : a New
Look at Surveillance Based on Emerging Estimates of
Cancer risk. American Journal of Gastroenterology
.94(8):2043-53,1999 Aug.
54. Robetro De Giorgio, Massimo P. Esophageal and
Gastric Nitrc Oxide Synthesizing Innervation in Primary
Achalasia The America Journal of Gastroenterology
Vol.94,No. 9,1999 2358-2362
55. Chandra Parkas et al. Botolinum Toxin Injections for
Achalasia Symptoms Can Approximate the Short Term
Efficacy of a Single Pneumatic Dilation: A Suvival
Analysis Approach The American Journal of
Gastroenterology Vol.94,No.2,1999 328-333
